Advanced

Diversity in antibody-based approaches to non-Hodgkin lymphoma

Maloney, David; Morschhauser, Franck; Lindén, Ola LU ; Hagenbeek, Anton and Gisselbrecht, Christian (2010) 7th International Workshop on Non-Hodgkins Lymphoma In Leukemia & Lymphoma 51. p.20-27
Abstract
Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for similar to 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that t arget CD20 antigens on the surface of malignant tumors. The use of mAbs, either as single agents or in combination with chemotherapy, has made a huge impact on NHL survival rates. Rituximab remains the most commonly used and established mAb, and is used in a wide range of NHLs, but does not produce an effective therapeutic response in all patients. Novel therapeutics with enhanced binding affinity or alternative antigen targets are currently in development and... (More)
Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for similar to 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that t arget CD20 antigens on the surface of malignant tumors. The use of mAbs, either as single agents or in combination with chemotherapy, has made a huge impact on NHL survival rates. Rituximab remains the most commonly used and established mAb, and is used in a wide range of NHLs, but does not produce an effective therapeutic response in all patients. Novel therapeutics with enhanced binding affinity or alternative antigen targets are currently in development and in some cases have demonstrated improved efficacy over currently available treatments. Radioimmunotherapy has been included in transplant conditioning regimens to improve long-term disease control while limiting toxicity. These regimens have been safe, effective, and feasible, and are therefore promising for patients who cannot tolerate high-dose chemotherapy and/or total body irradiation. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
keywords
monoclonal, Non-Hodgkin lymphoma, CD20, B cells, antibodies
in
Leukemia & Lymphoma
volume
51
pages
20 - 27
publisher
Taylor & Francis
conference name
7th International Workshop on Non-Hodgkins Lymphoma
external identifiers
  • wos:000282233100003
  • scopus:77956445009
ISSN
1042-8194
DOI
10.3109/10428194.2010.500047
language
English
LU publication?
yes
id
b9c7aac7-3b51-4e58-8ae5-b6110855187f (old id 1694782)
date added to LUP
2010-10-26 10:07:07
date last changed
2018-05-29 10:09:52
@inproceedings{b9c7aac7-3b51-4e58-8ae5-b6110855187f,
  abstract     = {Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for similar to 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that t arget CD20 antigens on the surface of malignant tumors. The use of mAbs, either as single agents or in combination with chemotherapy, has made a huge impact on NHL survival rates. Rituximab remains the most commonly used and established mAb, and is used in a wide range of NHLs, but does not produce an effective therapeutic response in all patients. Novel therapeutics with enhanced binding affinity or alternative antigen targets are currently in development and in some cases have demonstrated improved efficacy over currently available treatments. Radioimmunotherapy has been included in transplant conditioning regimens to improve long-term disease control while limiting toxicity. These regimens have been safe, effective, and feasible, and are therefore promising for patients who cannot tolerate high-dose chemotherapy and/or total body irradiation.},
  author       = {Maloney, David and Morschhauser, Franck and Lindén, Ola and Hagenbeek, Anton and Gisselbrecht, Christian},
  booktitle    = {Leukemia & Lymphoma},
  issn         = {1042-8194},
  keyword      = {monoclonal,Non-Hodgkin lymphoma,CD20,B cells,antibodies},
  language     = {eng},
  pages        = {20--27},
  publisher    = {Taylor & Francis},
  title        = {Diversity in antibody-based approaches to non-Hodgkin lymphoma},
  url          = {http://dx.doi.org/10.3109/10428194.2010.500047},
  volume       = {51},
  year         = {2010},
}